Shares of Sun Pharmaceutical Industries came under pressure in early trade, slipping nearly 4 percent after reports indicated that its long-evaluated acquisition of Organon has entered the final stages. The development marks a critical juncture in what could become one of the largest outbound deals by an Indian pharmaceutical company.

According to details available in the report, Organon has been on Sun Pharma’s radar for several months, with more serious internal evaluations beginning toward the end of November last year. The progression to an advanced stage suggests that negotiations, due diligence, and financing considerations may now be approaching closure, although no formal announcement has been made.

The potential deal aligns with a broader strategic shift articulated by Sun Pharma Chairman Dilip Shanghvi, who has repeatedly highlighted the need for Indian drugmakers to move beyond traditional generics and build capabilities in innovative and specialty therapies. Acquisitions, particularly in regulated markets, are being positioned as a faster route to scale and diversification.

Organon, a global healthcare company focused on women’s health and established medicines, represents a distinct opportunity in this context. For Sun Pharma, which already has a strong presence in generics and specialty segments, the acquisition could offer access to a differentiated portfolio and a broader international footprint. However, the scale of the proposed transaction reportedly around $12 billion—has triggered immediate investor caution.

The decline in Sun Pharma’s stock reflects concerns that typically accompany large cross-border acquisitions. These include uncertainties around integration, potential debt burden, and the ability to generate returns that justify the acquisition cost. In the absence of detailed disclosures on deal structure, funding mix, and expected synergies, markets appear to be pricing in execution risk.